Microbial Bioactive Metabolites in Cystic Fibrosis: Drivers of Chronic Lung Infection and Novel Therapeutic Targets
Microbial Bioactives · 01.06.2026 · 9 (1) · 1-8
DOI: 10.25163/microbbioacts.9110765 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbial Bioactives, online erschienen am 01.06.2026.
Abstract (Originalsprache)
Cystic fibrosis (CF) lung disease has traditionally been understood as a consequence of defective ion transport, impaired mucociliary clearance, and persistent bacterial colonization. Yet recent advances in metabolomics, microbiome science, and immunology suggest that this explanation, while still fundamentally valid, may capture only part of the disease process. Increasingly, the CF airway is being recognized as a metabolically active ecosystem in which host-derived lipids, microbial metabolites, inflammatory mediators, and immune signaling pathways interact continuously to shape chronic pulmonary injury. This narrative review synthesizes current evidence regarding microbial bioactive metabolites and their contribution to airway inflammation, pathogen adaptation, oxidative stress, and therapeutic resistance in CF. Particular attention is given to sphingolipid dysregulation, short-chain fatty acids, quorum-sensing molecules, immunometabolites such as succinate and itaconate, and gut–lung axis signaling. The review further explores the growing therapeutic relevance of natural bioactive compounds, sphingolipid modulators, and CFTR-targeted therapies in controlling chronic inflammatory and metabolic dysfunction. Collectively, the evidence suggests that microbial metabolites are not passive byproducts of infection but active regulators of airway ecology and disease persistence. Although important mechanistic uncertainties remain, emerging metabolomic insights may ultimately help redefine CF management through precision immunometabolism and multi-target therapeutic strategies aimed at disrupting the metabolic conditions that sustain chronic airway disease.
Zitieren
APA
(2026). Microbial Bioactive Metabolites in Cystic Fibrosis: Drivers of Chronic Lung Infection and Novel Therapeutic Targets. Microbial Bioactives, 9(1), 1-8. https://doi.org/10.25163/microbbioacts.9110765
Vancouver
Microbial Bioactive Metabolites in Cystic Fibrosis: Drivers of Chronic Lung Infection and Novel Therapeutic Targets. Microbial Bioactives. 2026;9(1):1-8. doi:10.25163/microbbioacts.9110765
BibTeX
@article{euvimed2026,
title = {Microbial Bioactive Metabolites in Cystic Fibrosis: Drivers of Chronic Lung Infection and Novel Therapeutic Targets},
journal = {Microbial Bioactives},
year = {2026},
volume = {9},
number = {1},
pages = {1--8},
doi = {10.25163/microbbioacts.9110765}
}
EUVIMED